Table 1. Patient characteristics.
| HCV/HIV | HCV | HIV | ||
| n = 14 | n = 19 | n = 10 | P-value | |
| General characteristics | ||||
| Age, median (IQR), years | 48 (14) | 55 (7) | 46 (6) | 0.12 |
| Gender, % male | 86% | 74% | 90% | 0.27 |
| ALT, median (IQR), IU/L | 65 (80) | 69 (85) | 30 (22) | <0.001 |
| HCV disease characteristics | ||||
| HCV-RNA, median (IQR), IU/mL | 1.9e6 (4.8e6) | 4.5e5 (1.1e6) | 0.07 | |
| Genotype, % genotype 1 | 75% | 79% | 1.00 | |
| History of HCV treatment: | 0.07 | |||
| Naïve, number (%) | 3 (21%) | 11 (58%) | ||
| Previously failed treatment, n (%) | 11 (79%) | 8 (42%) | ||
| Liver fibrosis/cirrhosis | 0.73 | |||
| F0–F2, number (%) | 8 (57%) | 9 (47%) | ||
| F3–F4, number (%) | 6 (43%) | 10 (53%) | ||
| HIV disease characteristics | ||||
| Viral load, copies/mL | All <50 | All <50 | – | |
| CD4-count, median (IQR),/mm3 | 540 (330) | 661 (247) | 0.11 | |
| HAART regimen | 0.70 | |||
| PI-based | 7 (50%) | 4 (40%) | ||
| Other regimens | 7 (50%) | 6 (60%) | ||
| Years of HAART, median | 13 | 8 | 0.35 |
General and disease-specific characteristics of patient groups. Abbreviations: ALT, alanine transaminase; IQR, interquartile range; PI, protease inhibitor; HAART, highly active antiretroviral treatment.